Clinical trial GO41892 - (CONTACT-01)
A phase III, multicenter, randomized, open-label, controlled study to evaluate the efficacy, safety, and pharmacokinetics of tezolizumab given in combination with cabozantinib versus docetaxel monotherapy in patients with metastatic non-small cell lung cancer previously treated with an anti-PD-L1/PD-1 antibody and platinum-containing chemotherapy
| Cancers | |
|---|---|
| Organ | Lung |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Roche |
| EudraCT Identifier | 2020-000100-11 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04471428 |
| Last update |